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Abstract
Background: Numerous post-licensure studies, mostly from field epidemiological evidences such as outbreak
surveys, have demonstrated the effectivenesss and insufficiency of one-dose varicella vaccine in outbreak control.
Serological evidence of immunization failure is, however, relatively less reported in contrast. A cross-sectional
seroepidemiological survey of Beijing residents was performed in 2012 in the People’s Republic of China, after the
one-dose varicella vaccine had been widely used for several years.
Methods: Multistage stratified random sampling method was designed to recruit 2 144 subjects. The ELISA method
was used to test the present blood samples collected and the reserve samples collected in 2008 to assess the
trends of anti-VZV seroprevalence in the past 5 years and to determine the risk factors for varicella infection.
Results: The age- and sex- adjusted overall anti-VZV seropositivity of Beijing residents in 2012 was 84.5 %. Two
groups’ adjusted overall anti-VZV seroprevalence in 2012 showed obvious growth compared with 2008 (<1 yr old:
from 6.3 % to 16.9 %; 1-4 yr old: from 27.6 % to 57.2 %). Reported one-dose vaccination history was 71.6 %
(149/208), 80.9 % (182/225) and 82.2 % (180/219) in the 1-4 yr, 5-9 yr, 10-14 yr age groups, respectively. Of subjects
who had received the one-dose vaccine, 36 % (216/603) showed negative anti-VZV concentrations (<110 mIU/mL);
additionally 15.9 % (96/603) of such subjects’ anti-VZV concentrations were in the lowest positive concentration
group (110-299 mIU/mL). Seropositivity in permanent residents of 1-9 yr old with verified vaccination was merely
61.8 %. Various age groups (1-3 yr, 4-6 yr, and 7-9 yr) all showed seropositivity that gradually decreased with
increasing of the interval between vaccination and blood sampling.
Conclusion: Mass varicella vaccination significantly improved the immunity of younger Beijing residents. However,
vaccine-induced anti-VZV antibody soon became weak in children with high coverage (approximately 80 %) after
vaccination for several years which is significantly higher than reported in pre-licensure studies. A government-funded
2-dose immunization program with mandatory vaccination schedule for Beijing residents may need consideration in
the near future.
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Background
Varicella (chickenpox) is a highly contagious disease
caused by infection with the primary varicella zoster virus
(VZV). Before implementation of the varicella vaccination
program in 1995, there were approximately four million
varicella cases per year [1] in the United States. Now,
varicella vaccines are available globally, some countries
have introduced them into the routine immunization pro-
gram for children, which has succeeded in reducing the
morbidity and mortality [2–4]. Numerous post-licensure
studies, mostly from field outbreak surveys, have showed
the field efficacy and insufficiency of one-dose varicella
vaccine in outbreaks control [5]. Based on data obtained
from the above-mentioned surveillance and field survey
evidence, several countries such as the United States have
begun to recommend a second dose of varicella vaccine.
However, the post-licensure serological evidences after
mass immunization are relatively much less reported [6].
Varicella was once considered a benign and common
childhood illness in the People’s Republic of China (PRC)
as well as in other countries; consequently, epidemio-
logical and serological data pre-licensure was rarely
available. The first varicella vaccine (Varilrix) was ini-
tially introduced in PRC by GlaxoSmithKline Biologi-
cals (Rixensart, Belgium) in 1998. Vaccination was not
widely accepted in PRC until the introduction of two
domestic vaccines (Changchun Keygen Biological Prod-
ucts Co., Ltd, Jilin, PRC and Shanghai Institute of Bio-
logical Products, Shanghai, PRC, both licensed in 2000).
Till date, there are total 4 vaccines licensed from domestic
manufacturers in PRC. Varicella vaccine has not been in-
cluded in the Expanded Program on Immunization at the
national level. In the capital city of Beijing, all vaccines for
all age groups are administered in public immunization
clinics, and there is no mandatory vaccination schedule of
varicella vaccine, which means that any child older than
one year can be vaccinated at any time. In Beijing, the
clincal varicella cases was notifiable since December 2006,
with a stable reported incidence in 2007-2010. In 2010, a
survey yielded a data that single-dose vaccine coverage
was achieved in 80.4 % of children 3-6 yr old [7]. However,
outbreaks caused by breakthrough varicella cases occurred
frequently in schools and kindergartens with high single-
dose vaccine coverage [8]. Thereafter, a cross-sectional
serological survey was performed in order to determine
the VZV seroprevalence in the one-dose era and the risk
factors of VZV infection in the whole population, which
would ultimately provide evidence-based references for
developing and adjusting the immunization strategy.
Methods
Survey design and subjects
The study was approved by Medical Ethics Committee
of the Beijing center for disease control (CDC) and
launched in June 2012. A multistage stratified random
sampling method was designed to recruit subjects.
According to geographic stratification, half of the urban,
suburban, and rural districts/counties (9/18) were sam-
pled as research sites. Ten communities/villages in each
district/county were systematically sampled as the survey
spots. At each survey spot, 20 subjects equally divided
between permanent residents and migrants as well as
divided between ten age groups (0, 1-4, 5-9, 10-14, 15-
19, 20-24, 25-29, 30-34, 35-39, ≥40 yr) were recruited.
The total sample size was expected to reach 2 000
people, with approximately 200 subjects of each age
group, and 50% each of permanent residents and mi-
grants. After the participants signed informed consent
by themselves or by parents/guardians in the case of
children, trained doctors used a standardized question-
naire along with a face-to-face interview to collect the
following information: sex, age, occupations, household
registration, recalled varicella history, and self-reported
vaccine administration history, which were also completed
by the parents/guardians in the case of children. In order
to obtain reliable proof, we verified the vaccination record
cards of permanent resident children 1-9 yr old.
To compare with previous serological data, we used
blood samples that were collected in another seroepide-
miological survey of epidemic cerebrospinal meningitis
in Beijing residents in 2008 to assess the differences and
trends of anti-VZV seroprevalence in the past 5 years. This
study appointed six districts/counties as research sites,
including one urban, two suburban, and three rural
districts/counties. Each research site had recruited approxi-
mately 220 to 240 subjects. Most of the recruited subjects
were children and adolescents. Unfortunately, this study
did not collect sufficient information of the subjects, except
for age, sex, and region, as well as vaccination history.
Laboratory testing
All samples were stored at 7 °C and transported to the
Beijing CDC within 24 hr, then centrifuged and frozen
at −20 °C. Samples were tested for IgG-class antibodies
to VZV with quantitative enzyme immunoassays accord-
ing to manufacturer instructions. The serological test is
a microplate enzyme-linked immunosorbent assay system
that uses purified antigen (cell lysate of a human fibroblast
cell line, VZV wild strain) to detect VZV IgG (EUROIM-
MUN Anti-Varicella-Zoster-Virus IgG-ELISA; Medizi-
nische Labordiagnostika AG, Lübeck, Germany). Positive
results (≥110 mIU/mL) were considered immune, negative
(<80 mIU/mL) and equivocal results (between 80 and 110
mIU/mL) were considered as not immune.
Statistical analyses
The database was created with Microsoft Excel (version
2007, Microsoft Corporation, USA). All statistical analyses
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were performed with SPSS, version 17 (SPSS Inc.,
Chicago, Illinois, USA). Frequencies were calculated for
categorical variables. We used Kruskal-Wallis or Mantel-
Haenszel Chi-square tests to evaluate the distribution of
continuous or categorical variables and a P-value of <0.05
was considered as significant. The overall seroprevalence
was age- and sex-adjusted according to an official 2010
population composition of Beijing residents, which was
obtained from the National population Census that is
launched every five years.
Results
Demographic characteristics of the subjects
A total of 2 144 subjects were recruited in the 2012 sur-
vey. Male and female subjects comprised approximately
50 % each; a similar proportion was ensured regarding
permanent residents and migrants. People from urban,
suburban, and rural areas accounted for 20.9 %, 21.5 %,
and 57.6 % of the subjects, respectively. Seven age
groups showed successful recruitment of more than 200
subjects. The other three age groups were unable to
do so (20-24 yr: 184 subjects; 25-29 yr: 185 subjects;
35-39 yr: 196 subjects). A total of 7.4 % of the overall
subjects acknowledged to suffering from varicella once;
this was 0 %, 0 %, 4.9 %, and 7.3 % in the age groups <1 yr,
1-4 yr, 5-9 yr, and 10-14 yr, respectively.
In the 2008 survey, 1 421 subjects were recruited. The
proportion of male and female subjects was 44.5 % and
55.5 %, respectively. Subjects from urban, suburban, and
rural areas accounted for 17.0 %, 33.5 %, and 49.5 %
subjects, respectively. Most of the subjects (1 056/1 421)
were below 20 yr old.
There was significant difference of geographic regions
(P < 0.001), sexes (P = 0.007), and age group distribution
(P < 0.001) between the subjects of the 2012 and 2008
studies. The data regarding household registration and
occupation distribution was not available for comparison
due to this data not being collected in the 2008 survey
(Table 1).
Seroprevalence comparison: 2012 versus 2008
Seroprevalence was seen in 72.9 % (1 572/2 144) sub-
jects aged 0-74 yr; the age- and sex- adjusted overall
anti-VZV seropositivity was 84.5 % as seen in the 2012
survey. Subjects aged ≥30 yr recorded the highest sero-
prevalence rate (93.7 %, 1212/1293), while the lowest rates
were recorded for subjects aged <1 yr (16.9 %, 13/77). In
the 2008 survey, 54.8 % (778/1 421) subjects aged 0-76 yr
were seropositive; however, the age- and sex-adjusted
overall anti-VZV seropositivity was 83.5 %. There was no
statistically significant difference in the adjusted overall
anti-VZV seropositivity of Beijing residents in 2008 and
that in 2012 (P = 0.243).
Two age groups showed an increase in sex-adjusted
seropositivity (< 1 yr old: from 6.3 % in 2008 to 16.9 %
in 2012, P = 0.019; 1-4 yr old: from 27.6 % in 2008 to
57.2 % in 2012, P = 0.006). No significant differences
were found in other age groups (5-9, 10-14, 15-19, 20-
29, and ≥ 30 yr old). (Table 2)
Self-reported varicella vaccine administration history
A total of 26.3 % (563/2 144) subjects reported having
received one-dose vaccine, which was 71.6 % (149/208),
80.9 % (182/225), 82.2 % (180/219), and 29.0 % (64/221)
in the age groups 1-4 yr, 5-9 yr, 10-14 yr, and 15-19 yr,
respectively. Most subjects older than 20 yr reported
their vaccination history as unknown. Permanent resi-
dents’ vaccine coverage (30.8 %, 335/1086) was slightly
higher than that of the migrants (25.5 %, 270/1058).
(Table 3)
Anti-VZV concentration in the 2012 survey
The mean anti-VZV concentration was 1574.9 (95 % CI
1503.9- 1645.9) mIU/mL. In the age-specific analysis,
Table 1 Demographic characteristics of subjects in serological






n (%) n (%)
Geographic regiona <0.001
Urban 440 (20.5) 241 (17.0)
Suburb 464 (21.6) 476 (33.5)
Rural 1240 (57.8) 704 (49.5)
Gender 0.007
Male 1054 (49.2) 632 (44.5)
Female 1090 (50.8) 789 (55.5)
Age <0.001
<1 year 196 (9.1) 171 (12.0)
1-4 years 208 (9.7) 350 (24.6)
5-9 years 225 (10.5) 222 (15.6)
10-14 years 219 (10.2) 132 (9.3)
15-19 years 221 (10.3) 181 (12.7)
20-29 years 430 (20.1) 119 (8.4)
≥30 years 645 (30.1) 246 (17.3)
Residency
Permanent residents 1086 (50.7) NA
Migrants 1058 (49.3) NA
Recalled Varicella History
Acknowledge 158 (7.4) NA
Deny 1986 (92.6) NA
aGeographic regions within Beijing were defined as rural, suburb and urban
according to the level of urbanization in each district/county
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subjects aged <1 yr were the lowest, with a mean anti-
VZV concentration of 103.0 (95 % CI 47.4- 158.5) mIU/
mL. The mean anti-VZV concentration increased stead-
ily with increasing age, reaching the highest in subjects
aged ≥30 yr, with a mean of 2141.2 (95 % CI 47.4- 158.5)
mIU/mL (P < 0.001).
There were statistically significant differences in the
anti-VZV concentrations between vaccination status
(P < 0.001) and age groups (P < 0.001), but no difference
was seen between sexes (P = 0.221). What is noteworthy is
that 36 % (216/603) of subjects who had received the anti-
VZV concentrations of the one-dose vaccine are negative
(<110 mIU/mL); additionally 15.9 % (96/603) of such sub-
jects’ anti-VZV concentrations belonged to the lowest
positive concentration group (110-299 mIU/mL).
Reversal phenomenon was also found in the age-
specific composition of different anti-VZV concentration
groups. The proportion of subjects aged 5-9 yr (49.3 %,
111/225) was higher than that of subjects aged 1-4 yr
(42.8 %, 89/208) in the negative concentration group
(<110 mIU/mL); however, this (15.1 %, 34/225) immedi-
ately changed and was lower in subjects aged 1-4 yr
(25.0 %, 52/208) in the lowest positive concentration
group (110-299 mIU/mL) (Fig. 1).
Table 2 Anti-VZV Seroprevalence of Beijing residents in 2012 and 2008, PRC









Overall 1559 (72.7) 778 (54.8) 1822(84.5) 1187(83.5) 0.243
Geographic region
Urban 315 (71.6) 124 (51.5) NA NA
Suburb 357 (76.9) 277 (58.2) NA NA
Rural 887 (71.5) 377 (53.6) NA NA
Gender
Male 734 (69.6) 297 (47.0) 922 (87.5) 598 (94.6) <0.001
Female 825 (75.7) 481 (61.0) 885 (81.2) 589 (74.7) 0.001
Age
<1 year 33 (16.8) 12 (7.0) 13 (16.9) 3 (6.3) 0.019
1-4 years 119 (57.2) 98 (28.0) 31 (57.2) 10 (27.6) 0.006
5-9 years 114 (50.7) 93 (41.9) 27 (50.4) 15 (42.0) 0.438
10-14 years 147 (67.1) 84 (63.6) 79 (67.1) 50 (64.0) 0.651
15-19 years 169 (76.5) 152 (84.0) 221 (76.4) 161 (84.0) 0.058
20-29years 372 (86.5) 106 (89.1) 224 (86.4) 150 (87.5) 0.721
≥30 years 605 (93.8) 233 (94.7) 1212 (93.7) 798 (93.1) 0.593
Household Registration
Permanent residents 804 (74.3) NA NA NA NA
Migrants 762 (71.5) NA NA NA NA
aOverall VZV+ n and positivity were age- and sex- adjusted. Male and female VZV+ n and positivity were age-adjusted. Age-specific VZV+ n and positivity were
sex- adjusted. Adjustments were according to a standard 2010 China population coming from National population Census. **Comparison of the unadjusted and
adjuested VZV+ positivity respectively, year 2012 vs. year 2008
Table 3 Varicella Vaccine administration history of subjects in
serological surveys of Beijing Residents in 2012, PRC
Self-reported vaccination history (N = 2144)
0-dose, n (%) 1-dose, n (%) Unknown, n (%)
Age
<1 year 196 (100.0) 0 (0) 0 (0)
1-4 years 59 (28.4) 149 (71.6) 0 (0)
5-9 years 43 (19.1) 182 (80.9) 0 (0)
10-14 years 32 (14.6) 180 (82.2) 7 (3.2)
15-19 years 70 (31.7) 64 (29.0) 87 (39.3)
20-29 years 75 (17.4) 22 (5.2) 333 (77.4)
≥30 years 66 (10.2) 6 (0.8) 573 (88.8)
Residency
Permanent residents 270 (24.9) 335 (30.8) 481 (44.3)
Migrants 271 (25.6) 270 (25.5) 519 (49.1)
Total 541 (25.2) 563 (26.3) 1000 (46.5)

























































Fig. 1 Distribution curves of anti-VZV concentration of Beijing residents in 2012 by a age group, b gender and c vaccine vaccination (n = 2157).
There were statistically significant differences in anti-VZV concentrations between age groups (P < 0.001) and vaccination status (P < 0.001), but no
difference between gender (P = 0.221), by x2 test
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Seroprevalence of permanent residents aged 1-9 years
based on verified vaccination records
Based on verified vaccination records, 19.5 % (44/226)
permanent residents who were 1-9 yr old in 2012 had
not received vaccine and another 1.3 % (3/226) subjects
acknowledged suffering from varicella. Thus, seropreva-
lence in a total of 165 subjects was analyzed based on
different age groups and different intervals between vac-
cination and blood sampling. The seropositivity of the
1-3 yr, 4-6 yr, and the 7-9 yr groups were 61.5 % (32/52),
58.5 % (38/65), and 66.7 % (32/48), respectively, a total of
61.8 % (102/165). All three age groups showed gradual
decrease in seropositivity with increasing interval between
vaccination and blood sampling (Fig. 2).
Discussion
To the best of our knowledge, our study is the first to
present the serological immunity against varicella as a
trend among all age groups of different residents in the
single-dose population and voluntary vaccination era in
Beijing, PRC. The overall and age-specific anti-VZV
seropositivity is slightly higher than seen in another
study reported by Shanghai scholars in 2012, where the
estimated one-dose vaccine coverage was 69.4 % in
children aged 4-6 ys [9]. This incidence is still lower
than that of countries that have introduced vaccines
in the national routine immunization schedule, such as
Korea [10] (89.6 %, 1-79 yr old in 2013) and the US [11]
(93.6 % of 6-19 yr old and 98.0 % of 20-49 yr old in 1999-
2004) with similar one-dose immunization indications.
Passive surveillance data provided the varicella epi-
demiological characteristics and vaccine coverage in
Beijing [7], which reports a stable annual incidence
(range:1.0-1.1/1 000 persons), a significant decrease of
incidence in children 1-4 yr old (vaccination age of most
children), and a peak incidence in children 5-9 yr old
between 2007 and 2010. It also illustrated that estimated
single-dose vaccine coverage could reach up to 80.4 % in
children 3-6 yr old in 2010.That means for each birth
cohort a few years earlier than 2010, vaccination cover-
age at a younger age (1-2 yr) is low (usually less than
50 %), which then increases with age; a higher vaccin-
ation coverage (approximately 80 %) can be achieved at
an older age (5-9 yr). Our study found that the adjusted
overall anti-VZV seroprevalence in two groups in 2012
showed significant growth compared with 2008 (< 1 yr
old: from 6.3 % to 16.9 %; 1-4 yr old: from 27.6 % to
57.2 %). This finding may indicate the success of mass
varicella vaccinations in increasing the immunity in
younger Beijing residents.
In clinical trials of the single-antigen varicella vaccine
that were conducted pre-licensure, seroconversion was
assessed by using several vaccines with different amounts
of PFUs and laboratory assays with different levels of sen-
sitivity and specificity. These studies usually reported high
short-term seroconversion [12, 13] after vaccination as
well as long-term persistence of antibody [14], especially
in vaccinated children. Relatively few post-licensure stud-
ies reported only 76 % seroconversion by using validated
sensitive and specific fluorescent antibodies to membrane
antigen (FAMA) assay [6]. Our study found that 36 %
(216/603) of the subjects who received one-dose varicella
vaccine were negative. Especially, the seropositivity of
permanent residents 1-9 yr old and older with verified one
dose vaccine was merely 61.8 %. Different age groups
(1-3 yr, 4-6 yr, and 7-9 yr) all showed gradually de-
creasing seropositivity with the increasing of the interval
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Fig. 2 Seroprevalence of 1-9 years permanent Beijing residents in 2012 who denied varicella history and had received one dose vaccine based
on verified vaccination records. Distribution of different age groups by different between vaccination and blood sampling interval (n = 165)
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domestic vaccines we focused on had reported good and
similar immunogenicity [15] (Changchun VS Shanghai:
92.3 % VS 88.3 %; total 659 children of 2-6 yr old; accord-
ing to FAMA test). However, another early clinical trial
reported that the Shanghai vaccine immunogenicity was
96 % after vaccination, which significantly decreased to
81.4 % two years later [16]. It is speculated that, in
addition to the reasons for the primary immunization
failure, the rate of antibody decline is faster than seen in
pre-licensure studies, which may be due to asymptomatic
boosting of vaccine-induced immunity, and the fact that
exposure to wild-type VZV is more impossible after exten-
sive application of vaccines and a dramatic decline in
incidence.
The World Health Organization recommends 2-dose
routine childhood immunization against varicella in
countries ensuring a vaccine coverage ≥80 %, as seen in the
latest position paper [17]. The ACIP has adopted new rec-
ommendations for a routine 2-dose varicella vaccination
program for children since 2006 with the second dose
given at age 4-6 yr old [18]. The first recommendation for
the booster dose of the varicella vaccine for children ≥4 yr
old in PRC was published in October 2012 by the Beijing
CDC. Additionally, a catch-up vaccination was also recom-
mended for children and adolescents who had previously
received the one-dose vaccine [19]. Nevertheless, the vari-
cella vaccine has still not been introduced in the national
immunization program until now, the single-dose vac-
cine coverage through voluntary vaccination strategies
has almost reached the maximum limit, and there is
still uncertainty regarding booster dose coverage. Given
the above challenges, a government-funded 2-dose
immunization program with mandatory vaccination
schedule for Beijing residents may need consideration
in the near future.
Our study has some limitations. The 2012 survey cov-
ered the whole population, with adolescents and adults
≥15 yr old accounting for more than 60 %, but most of
the recruit subjects were children and adolescents in the
historical data from the 2008 survey. The lack of adult sam-
ple may therefore affect the comparison of the overall anti-
VZV seropositivity of the entire population. Seroprevalence
evaluated by using ELISA does have limitations in sensitiv-
ity and specificity of the method [20, 21] which may under-
estimate the seropositivity of the antibody induced by the
vaccine. It is, however, not a problem for us to comprehen-
sively trace the entire picture of varicella seroprevalence in
Beijing residents from the single-dose vaccine indication
era. This can provide us a view into the degree of suscepti-
bility and infection risks in populations of different ages.
One more topic worth exploring is the immunization
failure occurring in the specific age group that received
one-dose vaccine after mass vaccination, which is signifi-
cantly higher than reported in previous studies.
Conclusion
In conclusion, our study found that mass single-dose
vaccination caused significant higher seropositivity in
subjects aged <1 yr and 1-4 yr in 2012 compared with
2008. However, vaccine-induced anti-VZV antibody soon
became weak in children with high coverage (approxi-
mately 80 %) after vaccination for several years. This
serological evidence is mutually validated by data ob-
tained from many field epidemiological evidences, such
as outbreaks surveys, which prove that the effectiveness
of one-dose varicella vaccine is insufficient. This pro-
vides us with another theoretical hypothesis to support
and suggest a government-funded vaccination program
including catch-up vaccination for children that needs to
be considered in the near future in Beijing.
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